December 2011 – Page 3 – Oral Cancer News

Medical Students Knowledge in the UK

Source: HighWire- Stanford University There has been little improvement in the survival of patients with oral cancer despite advances in treatment, and late presentation of the disease is one reason for this poor outcome. Research and experience tell us that tuition in medical schools about examination of the oral cavity is poor. We aimed to ascertain the opinions and experience of students regarding this in our institution by dissemination of a web-based anonymous questionnaire that focused on education about examination of the oral cavity and experience in carrying it out. From a cohort of 600 students 458 (76%) responded. A total of 334 (73%) had not been taught how to examine the oral cavity, 372 (81%) had had no experience of doing so in patients, and only 13/86 (15%) felt confident to diagnose a carcinoma of the lip or oral cavity. Eighty-nine percent felt that the tuition given had not been adequate. Examination of the oral cavity cannot be considered part of the core clinical curriculum, and medical schools and departments of oral and maxillofacial surgery urgently need to embrace the introduction of the necessary skills. This news story was resourced by the Oral Cancer Foundation, and vetted for appropriateness and accuracy.

Oral Cancer Foundation News Team - A2011-12-06T10:46:58-07:00December, 2011|Oral Cancer News|

Lymphedema Common After Head and Neck Cancer

Source: Elsevier Global Medical News SAN FRANCISCO (EGMN) - Lymphedema is highly common and a source of considerable morbidity among patients who undergo treatment for head and neck cancer, finds a cross-sectional study among 103 survivors. Fully three-fourths had developed some degree of lymphedema, according to results presented at the annual Oncology Congress presented by Reed Medical Education. The more severe it was, the more likely patients were to have symptoms, functional impairments, and poorer quality of life. Disease and treatment-related factors such as high radiation dose and combined surgery and radiation therapy were risk factors for the development of lymphedema. "This is the first study that we are aware of in the United States of this depth to systematically examine lymphedema" in this population, noted lead investigator Jie Deng, Ph.D., R.N., O.C.N., a postdoctoral fellow at the Vanderbilt University, Nashville, Tenn. "Health care professionals should be aware that lymphedema is a frequent late effect in the head and neck cancer population," she advised. "We need to educate patients about the risk of lymphedema prior to treatment, during treatment, and posttreatment, and we need to conduct external and internal examinations to evaluate related signs and symptoms at each clinic visit." Patients found to have any signs or symptoms should be referred for lymphedema assessment. Furthermore, "it's very important we have very detailed documentation so we can follow up on patients' treatment effect and also identify potential issues in this population," Dr. Deng stressed. "An interdisciplinary approach is needed to [...]

Oral Cancer Foundation News Team - A2011-12-06T10:29:30-07:00December, 2011|Oral Cancer News|

Boys need the cervical cancer jab, too

Source: www.telegraph.co.uk Author: Max Pemberton Few politicians will ever admit they are wrong, so I salute health ministers who have finally capitulated to medical opinion and last month announced a U-turn on the cervical cancer vaccine that is given to 12- and 13-year-old girls. Until now, Cervarix, which protects against two strains of the human papilloma virus (HPV) that are a factor in at least 70 per cent of diagnoses, has been the NHS vaccine of choice. However, another vaccine, Gardasil, also protects against a further two strains of HPV which cause genital warts, the most common sexually-transmitted infection, requiring costly and unpleasant treatment. As doctors have been arguing for some time, this has important public health implications. The current cost to the NHS of treating the 100,000 new cases of genital warts in England each year is £23 million. In several countries, including Australia, where Gardasil has been used in nationwide vaccination programmes, a 75 per cent decrease in the number of new cases of genital warts in the past three years has been reported. Critics of NHS policy complained that Cervarix was chosen over Gardasil not on the basis of clinical efficacy but because its manufacturers offered it at a discounted price, making it the most cost-effective. Indeed, many doctors have admitted in the medical press that they have bought Gardasil for their daughters privately, while they had to give their patients Cervarix. But ministers have seen sense as now Gardasil will be available on the NHS. But the [...]

Oral Cancer Foundation News Team - A2011-12-05T09:29:57-07:00December, 2011|Oral Cancer News|

Higher level of education linked to decreased mortality rates for oral cavity, pharynx cancers

Source: www.hemonctoday.com Author: Camille Ragin, PhD, MPH Overall mortality rates for oral cavity and pharynx cancer declined for all patient groups from 1993 to 2007, but high school graduates experienced the largest reductions in mortality compared with those who attained less than 12 years of education. Black men (–4.95%) and women with 12 years of education (–3.72%) experienced the largest decline in mortality. Black women with more than 12 years of education were the only group that did not experience significant decreases in mortality. Mortality rates increased significantly among all white men, except for those with more than 12 years of education. “Mortality rates for patients with oral cavity and pharynx cancers decreased significantly among men and women with more than 12 years of education, regardless of race/ethnicity (except for black women), whereas rates increased among white men with less than 12 years of education,” the researchers wrote. “Throughout the entire study period, mortality rates have remained highest among the least educated and lowest among those with some college education, regardless of sex or race/ethnicity.” Only patients with at least 12 years of education experienced decreases in mortality for HPV-unrelated cancer sites. Mortality rates increased 2.72% per year for white men with less than 12 years of education (P,.01). Conversely, mortality rates for HPV-related cancers decreased among black men. Among white men, mortality rates increased 1.58% per year for HPV-related cancers during the study period. People with more education typically have higher income, more resources and they’re more likely to [...]

Oral Cancer Foundation News Team - A2011-12-05T09:24:59-07:00December, 2011|Oral Cancer News|

The one thing Rick Perry did right: A shot that stops cancer, the politics of sex and HPV prevention

Source: CultureMap.com I don’t like Rick Perry — I never voted for him and worked actively to try to oust him — but in 2006 he tried to do something good for young girls in Texas. He tried to mandate vaccinations for sixth grade girls with a drug that prevented HPV (Human Papilloma Virus), the devil behind cervical cancer. This virus is responsible for the deaths of 4,000 young women each year in the United States. When Perry announced his mandate, the shit hit the fan and his conservative base (which is most of the state) went ballistic. The social conservatives objected to the vaccine as an infringement on parental rights, and small government conservatives were alarmed at Perry’s aggressive use of executive power. Needless to say, Perry backed off, and the vaccine was off to a miserable start. Six years later, fewer than 33 percent of girls ages 11 to 26 have received all three doses of the HPV vaccine, and Perry is still paying a political price for it. Not just for girls Well, it now appears that boys aren’t “immune” from HPV’s effects. After all, girls have to get infected from somewhere, right? Doctors have observed that young men were getting throat cancers that were usually seen in older, tobacco-using men. Also, there was an increase in anal cancers. Who do you think the culprit behind this was? HPV. It turns out that HPV is the most common sexually transmitted disease: between 75 and 80 percent of [...]

Oral Cancer Foundation News Team - A2011-12-02T12:39:52-07:00December, 2011|Oral Cancer News|

HPV vaccine myths put health, lives at risk, say health leaders: Airing the facts

Source: TheNationsHealth.org Vaccination rates for human papillomavirus are lagging for teens, and a complicated web of confusion and misinformation may be to blame, according to public health leaders. Several strains of HPV can cause cervical cancer, and two vaccines, Gardasil and Cervarix, have been shown conclusively to defend against those strains. The Food and Drug Administration recommended in 2006 that girls receive the vaccine before they become sexually active so that they are protected at the outset. In 2009, FDA approved the use of the vaccine for boys as well. According to the Centers for Disease Control and Prevention, about 6 million people in the U.S. become infected with HPV each year and each year about 12,000 women are diagnosed with cervical cancer, leading to about 4,000 deaths. Studies have shown the vaccine to be overwhelmingly safe, CDC said. As of June 2011, about 35 million doses of Gardasil had been distributed in the United States. CDC’s adverse event tracking mechanisms reported about 18,000 adverse events, 92 percent of which were nonserious events, such as fainting, swelling at the injection site and headache. Sixty-eight deaths were reported, but there is “no unusual pattern or clustering to the deaths that would suggest that they were caused by the vaccine, and some reports indicated a cause of death unrelated to vaccination,” CDC said. And yet, fed perhaps by misinformation or squeamishness about the idea of their children becoming sexually active, some parents are opting not to vaccinate, and the vaccination rates are [...]

Oral Cancer Foundation News Team - A2011-12-01T12:41:51-07:00December, 2011|Oral Cancer News|

NephRx Licenses Patent for Oral Mucositis Treatment

Source: Dr.Bicuspid.com November 30, 2011 -- NephRx has gained rights to a U.S. patent related to the company's novel peptide NX002, which is being developed for the treatment of oral mucositis and diseases of the gastrointestinal tract. Rights to U.S. patent No. 8,017,576, "Methods and compositions to treat mucositis" -- which protects NX002 and related compounds -- have been exclusively licensed to NephRx by the University of Chicago, where the drug was discovered in the laboratory of Dr. F. Gary Toback. Previously, NephRx reported that NX002 had demonstrated significant efficacy when tested in well-validated animal models of oral mucositis. Animals treated with NX002 had reduced levels of oral ulceration and a more rapid recovery, with no evidence of toxicity. The company is preparing to conduct detailed toxicity studies necessary to move forward with the NX002 clinical program, according to NephRx President and CEO James Koziarz NX002 is a peptide derived from the naturally occurring growth factor AMP-18, which has been shown to stimulate the growth of epithelial cells and promote mucosal wound healing after injury. This news story was resourced by the Oral Cancer Foundation, and vetted for appropriateness and accuracy.

Oral Cancer Foundation News Team - A2011-12-01T12:31:52-07:00December, 2011|Oral Cancer News|

Europe Bans X-Ray Body Scanners

Source: AVWeb.com The European Commission decided in November to ban airport body scanning X-ray backscatter machines after studies found a small number of cancer cases linked to use of the devices. The decision affects all airports in Europe, with an exception for U.K. airports that will be allowed to test them, but not deploy them permanently. According to the European Commission, "only security scanners which do not use X-ray technology are added to the list of authorized methods for passenger screening at EU airports." The commission does approve of full non-X-ray body scanners (radio wave scanners are among those used in the U.S.) when operated under specific guidelines and restrictions. In the U.S., the TSA uses more than 250 backscatter machines at the nation's 100 busiest airports and is unmoved by Europe's position. The degree of cancer risk varies somewhat depending on the source ... as does the degree of usefulness of the machines themselves. According to the U.S. Food and Drug Administration, backscatter machines bring a cancer risk of one in 400 million. Research reported by PBS Newshour/ProPublica states that the risk of developing cancer from the machines is "anywhere from six to 100" passengers per year. In a detailed paper submitted to the White House, University of California researchers said that because backscatter X-ray energy is absorbed mainly by the skin and underlying tissue, the skin dosage may be dangerously high in localized areas. The TSA says the amount of radiation emitted by a backscatter machine is similar [...]

Oral Cancer Foundation News Team - A2011-12-01T12:22:27-07:00December, 2011|Oral Cancer News|

New Report: States Slash Tobacco Prevention Funding by 36%, Spend Less than 2 Cents of Every Tobacco Dollar to Fight Tobacco Use

Source: TobaccoFreeKids.org WASHINGTON, DC – States have slashed funding for programs to reduce tobacco use by 12 percent in the past year and by 36 percent over the past four years, threatening the nation’s progress against tobacco, according to a report released today by a coalition of public health organizations. The states this year (Fiscal Year 2012) will collect a near-record $25.6 billion in revenue from the 1998 state tobacco settlement and tobacco taxes, but will spend only 1.8 percent of it – $456.7 million – on programs to prevent kids from smoking and help smokers quit. This means the states are spending less than two cents of every dollar in tobacco revenue to fight tobacco use. Both the total amounts states are spending on tobacco prevention programs and the percentage of tobacco revenue spent on these programs are the lowest since 1999, when the states first received significant tobacco settlement funds. With nearly 20 percent of Americans still smoking, the report warns that continued progress against tobacco use – the nation’s number one cause of preventable death – is at risk unless states increase funding for tobacco prevention and cessation programs. The report also calls on states to increase tobacco taxes and, for states that have yet to do so, to enact strong smoke-free laws that apply to all workplaces, restaurants and bars. The report further calls on the federal government to launch a national tobacco prevention and cessation campaign, including a mass-media campaign and support for telephone quitlines, [...]

Oral Cancer Foundation News Team - A2011-12-01T12:15:26-07:00December, 2011|Oral Cancer News|